Repurposed cancer drug to enter Phase I trials for Alzheimer’s disease this year
In the world of Alzheimer’s disease drugs, the past year has been marked by disappointing Phase 3 clinical trial results for a handful of much-anticipated antibody drugs. But the failure of those drugs, designed to clear toxic beta amyloid plaques that accumulate in the brain, isn’t discouraging to Cleveland startup ReXceptor Inc., which has just […]